

Comments on ACD from Liverpool Reviews and Implementation Group

Dear Elisabeth

We have reviewed the comments that you have received from Roche for this STA.

As discussed before Christmas, the ERG team was not consulted regarding the requests set out in the ACD. Had we been consulted we would have maintained the position that we took in our report and at the AC meeting, i.e. that the submitted economic model results are too heavily affected by extensive and unquantifiable uncertainty around the central claims of clinical benefit to be useful for decision making, and that the ERG concludes that the clinical data available make it impossible to compare the cost effectiveness of first-line RTX maintenance vs observation in patients with fNHL with any confidence.

Re-manipulation of these limited data therefore does not address any of the existing uncertainties.

Given this, we have no comments to make on the manufacturer's response. Also, given that the committee has already considered the position of the ERG and presented a positive opinion in this STA, we do not see that there is any purpose to be served by our attendance at the second AC.

If you have any questions please feel free to contact me.

